Member Info for sharehunter3

like how new buyers replacing sellers ,thinking will £4 be seen this morning or afternoon ,as sellers being replaced with different buyers

bought some more ,,before next move up

• Primerdesign revenue increased over 2,000% to €70.6m (H1 2019: €3.3m) due to the success of the COVID-19 product portfolio

Financial highlights

• Group consolidated unaudited revenue increased over 900% to €72.4m (H1 2019: €7.2m)

• Primerdesign revenue increased over 2,000% to €70.6m (H1 2019: €3.3m) due to the success of the COVID-19 product portfolio

• Group gross margin strengthened to 83%, delivering a gross profit of €60.3m, an increase of 20% from H1 2019 (63%)

• Primerdesign maintained its strong gross margin, delivering 85% in H1 2020 (H1 2019: 86%), demonstrating strong control of margins as the business is scaled

• Group EBITDA of €49.4m (H1 2019: €0.2m)

• Operating profit of €48.3m compared to a loss of €0.7m in H1 2019, driven by the growth in sales in molecular products business

• Profit after tax of €40.2m compared to a loss of €1.2m in H1 2019

• Cash at 30 June 2020 of €19.7m after paying down all long-term debt and significant working capital investment made into stock to ensure the continuity of supply to meet the demand for COVID-19 tests

Summary highlights

• H1 2020 sales of €72.4 million and EBITDA of €49.4 million, resulting from the sale of the Company's market leading PCR COVID-19 test, has transformed Novacyt

• Performance provides period end cash of €19.7m, following repayment of all debt and significant investment in inventory

• New strategy implemented to continue growth trajectory and consolidate performance through broadening focus on respiratory and transplant clinical diagnostics

• Visibility of orders for the Company's COVID-19 product portfolio suggests H2 2020 performance on track to exceed that of H1 2020

will £4 be seen this time, buys building nicely

• Acquisition of specific assets to enable Novacyt to expand its core capabilities whilst maintaining attractive margins

watch out for more news ,be my view ,

Strategy update highlights

• New strategy to focus on organic, R&D and acquisitive growth in the respiratory and transplant bacterial and viral diagnostic markets

• Investment in R&D and commercial infrastructure to deliver new products and establish a direct sales force in key markets in the US and across Europe

• Selective product/technology and company acquisitions to generate additional revenues and profits to offset potential future reductions in COVID-19 revenues and enhance the Group's trajectory towards becoming a market leader in respiratory and transplant clinical diagnostics

• Acquisition of specific assets to enable Novacyt to expand its core capabilities whilst maintaining attractive margins

• Investment in developing new IP portfolio to enhance and secure future value

85% margin

buys moving in again ,another move up looks to be coming again

shanjo ,before today ,can not remember seeing to many posts from you at ncyt

Shanjo ,why spending so much time here with negative posts

IN TODAYS RNS
Financial highlights

• Group consolidated unaudited revenue increased over 900% to €72.4m (H1 2019: €7.2m)

• Primerdesign revenue increased over 2,000% to €70.6m (H1 2019: €3.3m) due to the success of the COVID-19 product portfolio

• Group gross margin strengthened to 83%, delivering a gross profit of €60.3m, an increase of 20% from H1 2019 (63%)

• Primerdesign maintained its strong gross margin, delivering 85% in H1 2020 (H1 2019: 86%), demonstrating strong control of margins as the business is scaled

• Group EBITDA of €49.4m (H1 2019: €0.2m)

• Operating profit of €48.3m compared to a loss of €0.7m in H1 2019, driven by the growth in sales in molecular products business

• Profit after tax of €40.2m compared to a loss of €1.2m in H1 2019

• Cash at 30 June 2020 of €19.7m after paying down all long-term debt and significant working capital investment made into stock to ensure the continuity of supply to meet the demand for COVID-19 tests

85% margin ,

stronger buying again ,as some load up to be holding if another rns is released Tomorrow, or soon ,
also looking at date the 26 th September is a Saturday ,Half Year Results ,not be released this year on the 26th ,maybe the Friday or Monday ,

a bit of a dip today , ncyt moving up as date for Half Year Results gets closer , will some investors see any dips as an opportunity to buy into fort ,like the potential at fort

will a tick be seen before close

some sellers today ,hoping blue day tomorrow ,ncyt seeing buyers moving in today before half year results

1 RNS Today at this time , in past ncyt have released 3 rns in one day ,and a number of rns during last 90 trading minutes ,
personly hoping no more rns today ,like morning rns better ,with so much news due ,ncyt might release more news at any time

with the £ millions ncyt has coming in weekly / monthly from global sales ,debt cleared ,new tests launched also new test also to be released soon , now ncyt has so many £ millions for R & D ,will they now pay investors a dividend